Salute e Benessere

Innocan Pharma Announces Promising Successful Results in Efficacy Trial of…

The Trial results affirm that Innocan's Product - a proprietary formulation of cannabinoids, vasoconstriction stimulators, and potent moisturizers - is highly effective in alleviating foot dryness and decreasing the risk of skin cracking, a precursor to bruising and subsequent diabetic complications in individuals with diabetes. The seven-day Trial involved a diverse group of male and female volunteers living with diabetes and suffering from dry skin. The Trial's primary benchmark - a...
PR Newswire
15/08/2023

Sanofi: Information concerning the total number of voting rights and shares -…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglementgénéral de l'Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of 2,529,036,828 € Registered office : 46, avenue de la Grande Armée - 75017 Paris - France...
Nasdaq GlobeNewswire
15/08/2023

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; August 15, 2023 –Genmab A/S (Nasdaq: GMAB) will increase its share capital by 18,700 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 963 shares at DKK 962.00, 1,525 shares at DKK 1,136.00, 1,635 shares at DKK 1,145.00, 1,671...
Nasdaq GlobeNewswire
15/08/2023

Transactions in connection with share buy-back program

Company announcement no. 40 - 2315 August 2023 Transactions in connection with share buy-back program On 3 August 2023 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 38 - 23. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules...
Nasdaq GlobeNewswire
15/08/2023

Curium Announces Achievement of Co-Primary Endpoints in Phase 2 of Its Phase 1/2…

/CT imaging. The SOLAR Phase 2 study was conducted in the U.S. and included a group of 26 patients with metastatic prostate cancer.Michael Patterson, CEO – North America at Curium, commented,“The milestone announced today demonstrates Curium's global commitment to driving innovations in prostate cancer diagnosis and treatment, and is extremely encouraging for prostate cancer patients. Our proven ability to reliably manufacture and distribute Cu-64 diagnostic agents throughout the U.S...
Nasdaq GlobeNewswire
15/08/2023

The patient engagement solutions market is anticipated to grow at a CAGR of…

The increasing adoption of patient engagement solutions is driven by their ability to facilitate active participation of patients in their own healthcare journey. Further, owing to better communication, shared decision-making, and personalized care, the patient engagement solutions market is anticipated to witness a healthy growth in the forecast period. The increasing adoption of patient engagement solutions is driven by their ability to facilitate active participation of patients in their…
PR Newswire
15/08/2023

The Innovation Collaborative™ Sees Double Digit Growth, Invites Digital Health…

In the past year, the Innovation Collaborative added digital health and AI/ML innovators such as Digital Diagnostics and Anumana to a group that included Mayo Clinic Platform, Medial EarlySign, Quadrant Health, Centaur Labs, Ground Truth Labs, Cardiologs, and others. In the past year, the Innovation Collaborative added digital health and AI/ML innovators such as Digital Diagnostics and Anumana to a group that included Mayo Clinic Platform, Medial EarlySign, Quadrant Health, Centaur Labs…
PR Newswire
15/08/2023

Wound Care Biologics Market to Reach $3.3 Billion, Globally, by 2032 at 6.1%…

Request Sample of the Report on Wound Care Biologics Market Forecast 2032- Allied Market Research- https://www.alliedmarketresearch.com/request-sample/10712 Request Sample of the Report on Wound Care Biologics Market Forecast 2032- Allied Market Research-https://www.alliedmarketresearch.com/request-sample/10712 Biologics are the treatment products that are extracted from living organisms, such as human cells, animal tissues, or microorganisms. Wound care biologics are widely used to...
PR Newswire
15/08/2023

Trading by management and close relations of management

Please read the full announcement in PDF Attachment 2023_55_Trading_by_management
Nasdaq GlobeNewswire
15/08/2023

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31…

LONDON and NEW YORK, Aug.15, 2023(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet need in this multi-billion-dollar market, today announced financial results for the twelve months ended March 31, 2023 and provided a corporate update on its lead program in development. Gary Jacob, Chief Executive Officer of OKYO, commented, “We are very...
Nasdaq GlobeNewswire
15/08/2023

Bios Health Group Enters the Market to Offer Investment-Driven and Clinical…

Bios Health Group Chief Executive Officer, Zizi Uzezi Imatorbhebhe, MBA MS PMP®, says: "We are thrilled to bring this comprehensive suite of end-to-end solutions to Biotech and Life Science companies. Our strategic approach involves engagement with Venture Capitalists and Investors, effectively addressing the funding gap that often impedes early-stage Biotech companies from accessing critical financial resources required to realize their innovative concepts. Additionally, we provide…
PR Newswire
15/08/2023

Evoke launches audience intelligence offering to unlock full commercial…

Evoke's audience intelligence offering is an omnichannel-ready, future-proofed solution that utilizes data with unmatched precision and provides critical insights on patients, caregivers, healthcare professionals, and payors. The offering features four core solutions designed to reveal pain points and unlock commercial potential. Evoke's audience intelligence offering is an omnichannel-ready, future-proofed solution that utilizes data with unmatched precision and provides critical insights on...
PR Newswire
15/08/2023

Akari Therapeutics, Plc Announces ADS Ratio Change

NEW YORK and LONDON, Aug.15, 2023(GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from one ADS representing one hundred ordinary shares to a new ratio of one ADS representing two thousand ordinary shares. The ratio change is expected to be effective on August 17,...
Nasdaq GlobeNewswire
15/08/2023

Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for…

Foralumab to advance into Phase 2 human clinical trials using the world's only fully human intranasal anti-CD3 monoclonal antibodyTrial to be overseen by Brigham and Women's Hospital, a founding member of Mass General Brigham Healthcare System NEW YORK, Aug.15, 2023(GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced...
Nasdaq GlobeNewswire
15/08/2023

AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical…

– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023– Company to host conference call and webcast today at 8:30 AM ET OCALA, Fla., Aug.15, 2023(GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the second quarter 2023 and provided a business update. As previously announced, the Company will host a...
Nasdaq GlobeNewswire
15/08/2023

Bulletin from Swedish Orphan Biovitrum (Sobi)'s Extraordinary General Meeting…

The EGM resolved to authorise the Board of Directors to, during the period up to the Annual General Meeting 2024, resolve on issue of new common shares with preferential rights for the company's shareholders. The total number of shares that may be issued shall amount to the number of shares that corresponds to issue proceeds of approximately SEK 6,000,000,000 and shall be within the limits of the share capital. The purpose of the authorisation is to repay part of the bridge loan that partly…
PR Newswire
15/08/2023

Maypharm Launches METOO FILL HA FILLER, Metox botulinum toxin with a 2nd…

METOOFILL hyaluronic acid dermal filler (CE Approved), made by Maypharm CO, LTD, overcame the limitations of traditional hyaluronic acid cross-linking technology by using patented innovative three patented technologies. METOOFILL hyaluronic acid dermal filler (CE Approved), made by Maypharm CO, LTD, overcame the limitations of traditional hyaluronic acid cross-linking technology by using patented innovative three patented technologies. 1. Microbead Monophasic Technology This patented...
PR Newswire
15/08/2023

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial…

The analysis published in The Lancet shows that Nefecon demonstrated a highly statistically significant and clinically relevant benefit compared to placebo in eGFR over the two-year period of 9-months of treatment with Nefecon and 15-months of follow-up off drug. After the two-year period, there was a 6.11 mL/min/1.73 m2 decline in eGFR in the Nefecon arm compared with a 12.0 mL/min/1.73 m2 decline in the placebo arm, corresponding to a difference in two-year eGFR total slope of 2.95…
PR Newswire
15/08/2023

Successful FDA inspection at Aurisco's manufacturing site in Yangzhou, China

The inspection, carried out by the FDA Consumer Safety Officer, Mrs. Michele Glendenning, lasted 5 days (7–11.Aug.2023) as initially planned. The FDA inspection confirmed the site to be compliant with the principles and guidelines of Good Manufacturing Practices (GMP) and no Form 483 observations were issued. At the closing meeting the inspector informed that she was satisfied with the workshops and labs she had seen and complimented Aurisco on its GMP system and documents, inspection…
PR Newswire
15/08/2023

Novel biologic Ab-IPL-IL-17™ shows promise for rheumatoid arthritis and…

The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases. The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases. A paper published today in theAnnals of Rheumatic Diseases identifies the...
PR Newswire
15/08/2023

Aino Health AB (publ): interim report january-june 2023

This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail. Now we have 100 000 subscribers January–June 2023 Net sales were KSEK 11,971 (10,409) Profit/loss after financial items was KSEK -5,598 (-7,395) Earnings per share were SEK -0.1 (-0.2)April–June 2023 Net sales were KSEK 5,791 (4,985) Profit/loss after financial items was KSEK -2,807 (-3,673) Earnings per share were SEK -0...
Nasdaq GlobeNewswire
15/08/2023

Basilea reports strong revenue and profit growth in first half-year 2023

Increase in Cresemba ®and Zevtera ®related revenue to CHF 80.5 million (+57% year-on-year) Increase in operating profit to CHF 36.9 million and net profit to CHF 31.9 millionIncrease in cash and restricted cash to CHF 112.9 millionFull-year 2023 revenue and profit guidance increased Submitted US NDA for ceftobiprole in August Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, August 15, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX:...
Nasdaq GlobeNewswire
15/08/2023

Sandoz announces positive results from Mylight Phase lll study for biosimilar…

Mylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference afliberceptResults offer hope of new affordable option for patients with nAMD, a leading cause of visual impairment and progressive vision loss for older adults 1 Aflibercept is one of four high-value biosimilars that Sandoz plans to launch over next few years, further expanding patient access to high-quality biologics Basel, August 15, 2023— Sandoz, a global...
Nasdaq GlobeNewswire
15/08/2023

Tecan reports solid underlying sales growth in the first half of 2023 and…

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reportssolidunderlying sales growth in the first half of 2023and confirms its outlook for full year 2023Financial results for thefirst half of 2023 – Highlights Sales of CHF 541.5 million (H1 2022: CHF 584.0 million) Underlying growth of +6.8% in local currencies, excluding effects from lower COVID-related revenues and reduced ...
Nasdaq GlobeNewswire
15/08/2023
Altri  Comunicati